{"product_id":"human-hematopoietic-myeloid-leukemia-cell-line-aml14-3d10-bhc10902094","title":"Human Hematopoietic‐Myeloid Leukemia Cell Line (AML14.3D10)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThe AML14.3D10 cell line is the fully differentiated eosinophilic subline of the AML14 (Cat. T8171) cell line.\u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel identity:\u003c\/strong\u003e Human Hematopoietic‐Myeloid Leukemia Cell Line (AML14.3D10) is supplied as a tumor cell line derived from Human peripheral blood.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth properties:\u003c\/strong\u003e Suspension, round. Proliferates as an eosinophilic myelocyte to met amyelocyte, containing eosinophil secondary granules\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth conditions:\u003c\/strong\u003e PriCoat™ T25 Flasks (G299) are recommended for optimal cell culture. PriGrow II (TM002) + 8% FBS + 2mM L-glutamine (G275) + 1mM Sodium Pyruvate (TM057) + 50uM Beta- mercaptoethanol + 1% Penicillin\/Streptomycin Solution (G255), 37.0°C, 5% CO₂. Note: Cells are difficult to recover from freeze-thaw conditions and typically show 20-30% viability post-thaw; allow cells to recover in the first 72 hours through frequent media changes. It is absolutely imperative to perform a cell viabilty count each time cells are passaged to keep them between 3 x 105 – 1 x 106 maximum\/ml. Do not allow the cells to achieve a density greater than 8 X 105 viable cells\/ml.; this will lead to terminal differentiation and cell death. Addition of 100 pg\/ml GM-CSF to the culture media during the first week post-thaw will allow for more rapid recovery and improved cell viability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct format:\u003c\/strong\u003e Frozen, BSL-2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis cell-based model is generally used in immunology, hematology, and signaling studies. Donor\/background information is available for contextual interpretation.\u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eThese cells maintain an eosinophilic phenotype and proliferate without the addition of exogenous cytokines. AML14.3D10 proliferates rapidly in response to GM-CSF and IL-5 and expresses the α‐subunit of the IL‐3 receptor. Donor\/background information provided for this product: Male, 68, FAB M2 Acute Myeloid Leukemia.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.\u003c\/li\u003e\n\u003cli\u003eEngineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.\u003c\/li\u003e\n\u003cli\u003eWhen metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.\u003c\/li\u003e\n\u003cli\u003eAssay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.\u003c\/li\u003e\n\u003cli\u003eSide-by-side comparison of engineered versus parental background characteristics when relevant to the study design.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eChanges in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMorphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.\u003c\/li\u003e\n\u003cli\u003eMatched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCulture and product details\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Conditions:\u003c\/strong\u003e PriCoat™ T25 Flasks (G299) are recommended for optimal cell culture. PriGrow II (TM002) + 8% FBS + 2mM L-glutamine (G275) + 1mM Sodium Pyruvate (TM057) + 50uM Beta- mercaptoethanol + 1% Penicillin\/Streptomycin Solution (G255), 37.0°C, 5% CO₂. Note: Cells are difficult to recover from freeze-thaw conditions and typically show 20-30% viability post-thaw; allow cells to recover in the first 72 hours through frequent media changes. It is absolutely imperative to perform a cell viabilty count each time cells are passaged to keep them between 3 x 105 – 1 x 106 maximum\/ml. Do not allow the cells to achieve a density greater than 8 X 105 viable cells\/ml.; this will lead to terminal differentiation and cell death. Addition of 100 pg\/ml GM-CSF to the culture media during the first week post-thaw will allow for more rapid recovery and improved cell viability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSeeding Density (cells\/ml):\u003c\/strong\u003e 30,000 - 35,000 (every 3-4 days) DO NOT ALLOW CELLS TO EXCEED 1 x 10^6 CELLS\/ML\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Applied Biological Materials (abm) Inc.","offers":[{"title":"1x10\u003csup\u003e6\u003c\/sup\u003e cells \/ 1.0 ml","offer_id":53180540617069,"sku":"T8172","price":587.1,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/HzlgTmwnoWsgtQ7X5Xbuf1WjySivH94L4dkKsCga.png?v=1782151797","url":"https:\/\/www.ebiohippo.com\/products\/human-hematopoietic-myeloid-leukemia-cell-line-aml14-3d10-bhc10902094","provider":"BioHippo","version":"1.0","type":"link"}